Developer docs
API playgroundTry for free, no card

Search company profiles

Celsius Therapeutics

Full company profile

uuid0000hy9

Namestring
Celsius Therapeutics
Websiteurl
celsiustx.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Celsius Therapeutics was a Cambridge, Massachusetts-based biotechnology company founded in 2018 to develop precision medicines for patients with cancer and autoimmune disease, with a primary operational focus on inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis. The company built an AI-driven drug discovery platform designed to identify and advance novel therapeutic candidates, progressing its lead IBD drug into clinical-stage development. The platform was positioned around a proprietary, novel-method architecture for target identification in immune-mediated diseases, supported by a founding team of leading academic immunologists and computational biologists.

The business model was a pre-revenue, R&D-intensive biotech model rather than a commercial product model. Celsius did not sell drugs, license its platform to third parties for recurring fees, or operate distribution channels. Instead, it raised venture capital to fund internal drug development, ultimately targeting acquisition or partnership with a larger pharmaceutical company. The company raised approximately $148 million in total disclosed venture funding across a 2018 Series A (led by Third Rock Ventures, $65M) and a 2022 Series B (led by Casdin Capital, $83M), with participation from Google Ventures, Alexandria Venture Investments, Casdin Capital, Amgen Ventures, and others.

In June 2024, AbbVie acquired Celsius Therapeutics for $250 million, integrating the company and its IBD pipeline into AbbVie's immunology franchise. The acquisition occurred against a backdrop of consolidation in the techbio sector, where large pharmaceutical companies acquired later-stage private AI-biology assets. Following the acquisition, Celsius operates as a wholly-owned subsidiary within AbbVie, with no independent commercial operations, customers, or revenue stream of its own.

Short descriptiontext

Celsius Therapeutics is a Cambridge-based biotech that built an AI-driven drug discovery platform to develop precision medicines for inflammatory bowel disease and other immune-mediated conditions; acquired by AbbVie in June 2024.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
precision medicine development, AI drug discovery, inflammatory bowel disease therapeutics, single-cell genomics, immune-mediated disease treatments
Industry2 codes
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAF
Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Biotechnology Therapeutics
Social media profiles2 records
Cost components3 values
Personnel, Technology or R&D, Operations
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Celsius Therapeutics developed precision medicines for cancer and autoimmune disease, with a primary focus on inflammatory bowel disease (IBD). The company used AI-driven single-cell genomics and machine learning to identify novel therapeutic targets and advance drug candidates into clinical development for immune-mediated diseases.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Progressed IBD drug candidate to clinical stage
Product and service1 record
1Lead IBD Drug Candidate
CategoryInflammatory Bowel Disease Therapeutics
Description

Clinical-stage therapeutic candidate for inflammatory bowel disease (IBD), developed using AI-driven single-cell genomics analysis to identify novel targets in immune-mediated disease. Aimed at patients with IBD and targeted for acquisition/licensing by large pharmaceutical companies.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Machine-learning-driven drug discovery platform focused on predictive models of disease. Highly comparable to Celsius as an AI-native biotech; Insitro was similarly acquired by Eli Lilly in 2024, paralleling Celsius's exit via AbbVie.

TypeDirect peer
Description

AI-driven drug discovery company combining high-throughput biology with machine learning to advance a clinical pipeline. Closely comparable as a techbio platform company that progressed candidates to the clinic, although Recursion operates at much larger scale and is publicly listed.

TypeDirect peer
Description

Pioneer in AI-driven small molecule drug design with multiple clinical-stage candidates. Directly comparable as a techbio peer using AI to design therapeutics and recently merged with Recursion amid sector consolidation.

TypeDirect peer
Description

AI platform for drug discovery with a clinical pipeline in inflammatory and oncologic indications. Comparable techbio peer using knowledge graphs and ML to identify novel targets — overlapping therapeutic-area interest in immune-mediated disease.

TypeDirect peer
Description

AI/ML-enabled antibody discovery platform with multiple partnered clinical assets. Comparable as a techbio using machine learning to accelerate biologics discovery and generate clinical-stage therapeutic candidates.

TypeDirect peer
Description

Generative AI platform for designing novel protein therapeutics across multiple indications. Comparable AI-native biologics discovery peer with a similar 'platform-to-pipeline' model and pharma partnerships.

TypeDirect peer
Description

Single-cell-omics-driven drug discovery platform founded by Flagship Pioneering. Comparable to Celsius given co-founder Aviv Regev's parallel work in single-cell biology and the shared AI-omics-to-therapeutics approach.

TypeDirect peer
Description

AI biotech applying machine learning to biomedical data for target discovery and clinical development. Comparable as an AI-driven therapeutic discovery company, though Owkin is more diagnostics-and-trials focused.

TypeDirect peer
Description

AI-driven oncology drug development company using machine learning to identify responders and rescue/advance therapeutic candidates. Comparable techbio model at smaller scale and in oncology rather than autoimmune disease.

10Prometheus Biosciences
TypeDirect peer
Description

IBD-focused precision immunology biotech acquired by Merck for ~$11B in 2023. Closest therapeutic-area peer (same IBD/immunology focus) and a comparable exit-via-pharma-acquisition narrative at much larger scale.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Celsius Therapeutics

Biotechnology Therapeuticscelsiustx.com

Celsius Therapeutics is a Cambridge-based biotech that built an AI-driven drug discovery platform to develop precision medicines for inflammatory bowel disease and other immune-mediated conditions; acquired by AbbVie in June 2024.

What Celsius Therapeutics does

Celsius Therapeutics was a Cambridge, Massachusetts-based biotechnology company founded in 2018 to develop precision medicines for patients with cancer and autoimmune disease, with a primary operational focus on inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis. The company built an AI-driven drug discovery platform designed to identify and advance novel therapeutic candidates, progressing its lead IBD drug into clinical-stage development. The platform was positioned around a proprietary, novel-method architecture for target identification in immune-mediated diseases, supported by a founding team of leading academic immunologists and computational biologists.

The business model was a pre-revenue, R&D-intensive biotech model rather than a commercial product model. Celsius did not sell drugs, license its platform to third parties for recurring fees, or operate distribution channels. Instead, it raised venture capital to fund internal drug development, ultimately targeting acquisition or partnership with a larger pharmaceutical company. The company raised approximately $148 million in total disclosed venture funding across a 2018 Series A (led by Third Rock Ventures, $65M) and a 2022 Series B (led by Casdin Capital, $83M), with participation from Google Ventures, Alexandria Venture Investments, Casdin Capital, Amgen Ventures, and others.

In June 2024, AbbVie acquired Celsius Therapeutics for $250 million, integrating the company and its IBD pipeline into AbbVie's immunology franchise. The acquisition occurred against a backdrop of consolidation in the techbio sector, where large pharmaceutical companies acquired later-stage private AI-biology assets. Following the acquisition, Celsius operates as a wholly-owned subsidiary within AbbVie, with no independent commercial operations, customers, or revenue stream of its own.

Celsius Therapeutics firmographics

Firmographics
Name
Celsius Therapeutics
Website
https://celsiustx.com
Company type
Private
Founded year
2018
Operating status
Acquired
Headcount range
1–10 employees
Short description
Celsius Therapeutics is a Cambridge-based biotech that built an AI-driven drug discovery platform to develop precision medicines for inflammatory bowel disease and other immune-mediated conditions; acquired by AbbVie in June 2024.
Ownership category
akta.pro rank

Celsius Therapeutics industry classification

Industry
Product category
Biotechnology Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAF
Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Precision medicine development
  • AI drug discovery
  • Inflammatory bowel disease therapeutics
  • Single-cell genomics
  • Immune-mediated disease treatments

Where Celsius Therapeutics is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Markets served

Celsius Therapeutics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations

Celsius Therapeutics product offering

Product offering

Core offering

Celsius Therapeutics developed precision medicines for cancer and autoimmune disease, with a primary focus on inflammatory bowel disease (IBD). The company used AI-driven single-cell genomics and machine learning to identify novel therapeutic targets and advance drug candidates into clinical development for immune-mediated diseases.

Differentiator

Problem solved

Functional benefit

Products and services

  • Lead IBD Drug Candidate Clinical-stage therapeutic candidate for inflammatory bowel disease (IBD), developed using AI-driven single-cell genomics analysis to identify novel targets in immune-mediated disease. Aimed at patients with IBD and targeted for acquisition/licensing by large pharmaceutical companies.

Quantifiable outcome

  • Progressed IBD drug candidate to clinical stage

Companies that use Celsius Therapeutics

Customer profile

Segments1 record

Ideal customer profiles1 record

Celsius Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Celsius Therapeutics partnerships and signals

Strategic signal

Scale indicators2 records

Recent moves4 records

Expansion highlights4 records

Celsius Therapeutics competitors and assessment

Company assessment

Direct peers

  • Insitro: Machine-learning-driven drug discovery platform focused on predictive models of disease. Highly comparable to Celsius as an AI-native biotech; Insitro was similarly acquired by Eli Lilly in 2024, paralleling Celsius's exit via AbbVie.
  • Recursion Pharmaceuticals: AI-driven drug discovery company combining high-throughput biology with machine learning to advance a clinical pipeline. Closely comparable as a techbio platform company that progressed candidates to the clinic, although Recursion operates at much larger scale and is publicly listed.
  • Exscientia: Pioneer in AI-driven small molecule drug design with multiple clinical-stage candidates. Directly comparable as a techbio peer using AI to design therapeutics and recently merged with Recursion amid sector consolidation.
  • BenevolentAI: AI platform for drug discovery with a clinical pipeline in inflammatory and oncologic indications. Comparable techbio peer using knowledge graphs and ML to identify novel targets — overlapping therapeutic-area interest in immune-mediated disease.
  • AbCellera Biologics: AI/ML-enabled antibody discovery platform with multiple partnered clinical assets. Comparable as a techbio using machine learning to accelerate biologics discovery and generate clinical-stage therapeutic candidates.
  • Generate Biomedicines: Generative AI platform for designing novel protein therapeutics across multiple indications. Comparable AI-native biologics discovery peer with a similar 'platform-to-pipeline' model and pharma partnerships.
  • Cellarity: Single-cell-omics-driven drug discovery platform founded by Flagship Pioneering. Comparable to Celsius given co-founder Aviv Regev's parallel work in single-cell biology and the shared AI-omics-to-therapeutics approach.
  • Owkin: AI biotech applying machine learning to biomedical data for target discovery and clinical development. Comparable as an AI-driven therapeutic discovery company, though Owkin is more diagnostics-and-trials focused.
  • Lantern Pharma: AI-driven oncology drug development company using machine learning to identify responders and rescue/advance therapeutic candidates. Comparable techbio model at smaller scale and in oncology rather than autoimmune disease.
  • Prometheus Biosciences: IBD-focused precision immunology biotech acquired by Merck for ~$11B in 2023. Closest therapeutic-area peer (same IBD/immunology focus) and a comparable exit-via-pharma-acquisition narrative at much larger scale.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Celsius Therapeutics social profiles

Digital presence

Celsius Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Celsius Therapeutics leadership team

Management profile

Number of profiles

Profiles5 records

Celsius Therapeutics funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Celsius Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Celsius Therapeutics

What does Celsius Therapeutics do?

Celsius Therapeutics developed precision medicines for cancer and autoimmune disease, with a primary focus on inflammatory bowel disease (IBD). The company used AI-driven single-cell genomics and machine learning to identify novel therapeutic targets and advance drug candidates into clinical development for immune-mediated diseases.

Is Celsius Therapeutics a public or private company?

Celsius Therapeutics is a private company. It is classified as corporate owned and is currently acquired.

When was Celsius Therapeutics founded?

Celsius Therapeutics was founded in 2018. It employs 1 to 10 people.

Where is Celsius Therapeutics based?

Celsius Therapeutics is headquartered in Cambridge, United States, in the North America region.

Who are Celsius Therapeutics's main competitors?

Direct peers on record are Insitro, Recursion Pharmaceuticals, Exscientia, BenevolentAI, AbCellera Biologics, Generate Biomedicines, Cellarity, Owkin, Lantern Pharma and Prometheus Biosciences.

Does Celsius Therapeutics have an API?

No public API is recorded for Celsius Therapeutics.

What industry is Celsius Therapeutics in?

Celsius Therapeutics's product category is Biotechnology Therapeutics. Its primary akta.pro industry code is HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening), with a secondary code of HLAAAIAF, Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AbbvieAbbVie Acquires Celsius TherapeuticsAbbVie acquired Celsius Therapeutics for $250 million in cash, acquiring all outstanding Celsius equity. Celsius's lead asset, CEL383, is an anti-TREM1 antibody that completed a Phase 1 study for inflammatory bowel disease. The deal aims to advance CEL383 development for IBD treatment.MorningstarAbbVie Buys Celsius Therapeutics for $250 MillionAbbVie acquired clinical-stage biotech Celsius Therapeutics for $250 million in cash. Celsius' lead asset CEL383, a TREM1-targeting antibody, completed a Phase 1 study for inflammatory bowel disease. The deal expands AbbVie's pipeline for inflammatory diseases.PR NewswireAbbVie Acquires Celsius TherapeuticsAbbVie acquired Celsius Therapeutics for $250 million in cash, acquiring all outstanding Celsius equity. Celsius's lead asset, CEL383, is an anti-TREM1 antibody that completed a Phase 1 study for inflammatory bowel disease. AbbVie aims to advance CEL383's development for IBD treatment.PR NewswireApplied BioMath, LLC Announces a Continuation of their Collaboration with Celsius Therapeutics for Systems Pharmacology Modeling in Inflammatory Bowel DiseaseApplied BioMath announced a continuation of its collaboration with Celsius Therapeutics to develop a systems pharmacology model of a monoclonal antibody for treating inflammatory bowel disease (IBD). Applied BioMath will create in vitro and human systems pharmacology models to support human dose predictions as Celsius prepares for an Investigational New Drug (IND) filing. The collaboration was continued based on scientific excellence and a collaborative approach demonstrated in a prior project.BioSpaceCelsius Therapeutics Names Scientific AdvisersCelsius Therapeutics announced the appointment of six scientific advisers on Sept. 22, 2022. The advisers include experts in inflammatory bowel disease, oncology, immunobiology, single-cell genomics, and computational biology. The company is advancing its first programs into the clinic.BioSpaceCelsius Therapeutics Appoints Sarah Grant, M.D., as Chief Medical OfficerCelsius Therapeutics appointed Sarah Grant, M.D., as chief medical officer on Aug. 25, 2022. She will lead clinical strategy and development, including its anti-TREM1 antibody for inflammatory bowel disease. Grant brings over 20 years of experience, including nine years at Novartis.CelsiustxCelsius Therapeutics is now a part of AbbVieCelsius Therapeutics has been acquired by AbbVie, officially becoming part of the pharmaceutical company. This acquisition integrates Celsius into AbbVie's immunology division to further develop innovative medicines for immune-mediated diseases.PR NewswireApplied BioMath, LLC Announces Collaboration with Celsius Therapeutics for Systems Pharmacology Modeling in Inflammatory Bowel DiseaseApplied BioMath announced a collaboration with Celsius Therapeutics to develop a semi-mechanistic pharmacokinetic/receptor occupancy model for a monoclonal antibody targeting inflammatory bowel disease. Celsius Therapeutics will use the model to support human dose projections and inform their clinical strategy. The collaboration highlights Applied BioMath's role as a provider of model-informed drug discovery services to biotech and pharmaceutical companies seeking to de-risk therapeutic R&D.Prwebelluminate® Clinical Data Platform from eClinical Solutions Selected by Celsius Therapeutics to Speed Insights & Value of Clinical DataCelsius Therapeutics selected eClinical Solutions' elluminate clinical data platform for its research programs. The platform aggregates and standardizes clinical trial data, enabling rapid insights and improved data quality. Celsius uses it to build a database of single-cell genomic and patient clinical information for precision medicine discovery.NatureNature BiotechnologyMultiple biotech and pharma companies announced leadership appointments in July 2020, including Celsius Therapeutics naming Jeanne Magram as CSO and Rallybio appointing Róisín Armstrong to lead its lead program. Other appointments include Cedrik Britten as Immatics' CMO and Pierre-Alain Ruffieux as Lonza CEO.